Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Stifel analyst Alex Thompson reiterated a Buy rating and $41.00 price target on Viridian Therapeutic (NASDAQ: VRDN).

The analyst comments "Following two positive Ph3 studies from first-gen IV-program Veligrotug (LINK, LINK) demonstrating a differentiated profile vs. SoC Tepezza, we continue to view VRDN as uniquely positioned in the evolving TED space with the opportunity to launch in 2026 supported by a dataset enabling broader access vs. Tepezza. Importantly, PK matching with next-gen subcu VRDN-003 (shared epitope with Veligrotug) further de-risks the ongoing Ph3 program with data expected in 1H26. Meanwhile, data presented from subcu IGF-1R competitor, Lonigutamab, yesterday support the potential best-in-class VRDN-003 profile with Q4W and Q8W doses being tested in Ph3. Subcu PoC data from SLRN, while small N and open-label, suggest an efficacy/safety profile, which is at best comparable albeit with planned Ph3 dosing of Q2W (topline 2H26) – while likely preferable to the Q2W on-body device being tested for Tepezza, this is unlikely to be competitive with VRDN-003, in our view, especially if VRDN-003 replicates Veligrotug efficacy."

For an analyst ratings summary and ratings history on Viridian Therapeutic click here. For more ratings news on Viridian Therapeutic click here.

Shares of Viridian Therapeutic closed at $20.07 yesterday.

You May Also Be Interested In

• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Software M&A heats up: Which SaaS stocks could be next for private equity?
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform